OTC Cough & Cold Medicine Manufacturing in European Union 2026: Industry Statistics & Trends

The OTC cough and cold medicine manufacturing industry in the European Union focuses on the production of non-prescription respiratory treatments, including cough syrups, decongestants, and multi-symptom cold remedies. According to Eurostat PRODCOM data, the broader EU value of sold production for the manufacture of basic pharmaceutical products reached a peak of €54 billion in 2024, demonstrating strong growth in the region's pharmaceutical output. The industry is characterized by robust demand fueled by seasonal respiratory viruses and a strong consumer shift toward self-medication for mild ailments. Moving forward, the sector is steering toward sustainable packaging, plant-based or natura

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the OTC Cough & Cold Medicine Manufacturing in European Union industry cover?

This industry comprises establishments in the European Union primarily engaged in formulating, manufacturing, and packaging over-the-counter (OTC) medications used to alleviate symptoms of the common cold, influenza, and acute coughs. These products are manufactured in various dose forms such as syrups, tablets, capsules, lozenges, and nasal sprays, and are cleared for direct consumer purchase without a prescription.

• •Classified under the official European NACE Rev. 2 system within division 21 for pharmaceutical manufacturing.
• •Includes both chemical-based active ingredients (like paracetamol, dextromethorphan, and pseudoephedrine) and regulated herbal active substances.
• •Excludes prescription-only respiratory therapies and advanced bronchoflasm treatments requiring medical oversight.

Who operates in the industry and how is it structured?

The market structure is composed of a mix of major multinational pharmaceutical corporations, dedicated consumer healthcare spin-offs, and localized generic manufacturers operating production facilities across EU member states. Production is highly concentrated in key industrial hubs, with countries like Germany, France, and Italy leading the continent's overall pharmaceutical manufacturing output.

• •Germany recorded the highest value of sold industrial production in the EU at 26% of the total in 2024 according to Eurostat.
• •Contract Manufacturing Organizations (CMOs) play a critical role, allowing brand owners to outsource specialized liquid and solid dose manufacturing.
• •Facilities must hold strict European Good Manufacturing Practice (GMP) certifications issued by national competent authorities to operate.

What drives demand in the industry?

Demand for OTC cough and cold remedies is primarily driven by seasonal winter outbreaks of rhinovirus, influenza, and respiratory syncytial virus (RSV) across Europe. Additionally, public health policies encouraging self-care for minor ailments to alleviate strain on general practitioners have structurally shifted consumer behavior toward OTC solutions.

• •The aging European demographic increases the volume of consumers seeking accessible, safe symptom management for seasonal ailments.
• •Macroeconomic fluctuations influence consumer preference for affordable, private-label generic cough and cold formulations over premium brands.
• •Increased consumer awareness regarding lifestyle wellness drives the inclusion of immunity-supporting vitamins within traditional cold formulations.

Who are the notable companies in the industry?

The competitive landscape features intense rivalry among massive consumer health entities that manage well-recognized global and regional brands. These companies leverage extensive supply chains and multi-country production facilities located within the EU to ensure rapid distribution ahead of the peak cold and flu seasons.

• •Sanofi SA, headquartered in France, is a dominant operator with a massive consumer healthcare portfolio containing prominent allergy and cold brands.
• •Haleon plc, a major global consumer healthcare spin-off, maintains extensive operations and manufacturing footprints across several EU member states.
• •Bayer AG, based in Germany, manufactures globally recognized OTC brands and utilizes extensive automated production lines within the European single market.
• •Reckitt Benckiser Group plc operates substantial production networks in Europe, driving the manufacture of widespread medicated lozenges and cold remedies.

What are the recent trends and outlook?

Recent trends highlight a strategic push toward sustainable manufacturing processes, including reducing single-use plastics in blister packs and shifting to eco-friendly syrup bottles. Innovation is also focused on multi-symptom nighttime formulations and natural-ingredient integrations, while nearshoring supply chains remains a priority to mitigate active pharmaceutical ingredient (API) shortages.

• •Eurostat data shows the manufacture of pharmaceutical products and preparations achieved a 74% increase in sold production value in 2024 compared to 2014.
• •Rising manufacturing input costs for raw active ingredients and sustainable packaging are placing pressure on standard operator profit margins.
• •Digitalization of manufacturing facilities via AI-driven batch testing and automated sorting is optimizing production efficiency across regional plants.

How is the industry regulated?

Operators within the EU must comply with some of the world's most rigorous regulatory frameworks governing drug safety, efficacy, and marketing. The transition of certain active substances from prescription to OTC status (Directive 2001/83/EC) serves as a major mechanism for introduction of new consumer products.

• •All manufacturing facilities must adhere to European Union Good Manufacturing Practice (EU GMP) standards, verified via rigorous regulatory inspections.
• •The European Medicines Agency (EMA) and national bodies strictly monitor pharmacovigilance and clear labeling requirements for pediatric cough remedies.
• •The EU Falsified Medicines Directive requires safety features like anti-tampering devices on packaging, directly impacting final production-line configurations.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat Industrial Production Statistics (PRODCOM) 2024 ·
• Eurostat Trade and Production of Chemicals and Related Products 2024 ·
• European Medicines Agency (EMA) Manufacturing Authorization Guidelines ·
• European Commission Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use